Company intelligence / Profile preview

Shanghai Yunshengyan New Biotechnology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Shanghai Yunshengyan New Biotechnology is a Chinese biotechnology company focused on the discovery and development of innovative therapies for autoimmune and inflammatory diseases. The company specializes in targeting the IL-17 pathway, which is a critical driver in conditions such as psoriasis and atopic dermatitis. Their research efforts include the development of small molecule inhibitors and biologics designed to provide more effective and convenient treatment options for patients. By leveraging advanced drug discovery techniques, Yunshengyan aims to address significant unmet medical needs in the immunology space.

Therapeutic areas: ImmunologyDermatology
Modalities: Small moleculeAntibody
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Yunshengyan New Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Yunshengyan New Biotechnology.

Explore the full profile